Non-Coding Rnas As Potential Therapeutic Targets for Receptor Tyrosine Kinase Signaling in Solid Tumors: Current Status and Future Directions Publisher



Moeinafshar A^{1, 2} ; Nouri M³ ; Shokrollahi N³ ; Masrour M^{2, 4} ; Behnam A³ ; Tehrani Fateh S^{1, 2} ; Sadeghi H⁵ ; Miryounesi M^{1, 5} ; Ghasemi MR^{1, 5} Show Affiliations
Source: Cancer Cell International Published:2024

Abstract

This review article presents an in-depth analysis of the current state of research on receptor tyrosine kinase regulatory non-coding RNAs (RTK-RNAs) in solid tumors. RTK-RNAs belong to a class of non-coding RNAs (nc-RNAs) responsible for regulating the expression and activity of receptor tyrosine kinases (RTKs), which play a critical role in cancer development and progression. The article explores the molecular mechanisms through which RTK-RNAs modulate RTK signaling pathways and highlights recent advancements in the field. This include the identification of potential new RTK-RNAs and development of therapeutic strategies targeting RTK-RNAs. While the review discusses promising results from a variety of studies, encompassing in vitro, in vivo, and clinical investigations, it is important to acknowledge the challenges and limitations associated with targeting RTK-RNAs for therapeutic applications. Further studies involving various cancer cell lines, animal models, and ultimately, patients are necessary to validate the efficacy of targeting RTK-RNAs. The specificity of ncRNAs in targeting cellular pathways grants them tremendous potential, but careful consideration is required to minimize off-target effects, the article additionally discusses the potential clinical applications of RTK-RNAs as biomarkers for cancer diagnosis, prognosis, and treatment. In essence, by providing a comprehensive overview of the current understanding of RTK-RNAs in solid tumors, this review emphasizes their potential as therapeutic targets for cancer while acknowledging the associated challenges and limitations. © 2024, The Author(s).